Business Description
Mineralys Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US6031701013
Total Employee Number:
76Description
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.98 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -46.2 | |||||
3-Year EPS without NRI Growth Rate | -44.2 | |||||
3-Year FCF Growth Rate | -41.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.61 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.61 | |||||
9-Day RSI | 56.62 | |||||
14-Day RSI | 55.84 | |||||
3-1 Month Momentum % | -10.74 | |||||
6-1 Month Momentum % | -28.8 | |||||
12-1 Month Momentum % | 62.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 44.33 | |||||
Quick Ratio | 44.33 | |||||
Cash Ratio | 43.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.8 | |||||
Shareholder Yield % | -16.04 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -30.16 | |||||
ROA % | -29.13 | |||||
ROIC % | -4940 | |||||
3-Year ROIIC % | -3797.08 | |||||
ROC (Joel Greenblatt) % | -625901.46 | |||||
ROCE % | -34.08 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.67 | |||||
Price-to-Tangible-Book | 3.67 | |||||
EV-to-EBIT | -10.82 | |||||
EV-to-EBITDA | -10.82 | |||||
EV-to-Forward-Revenue | 26.31 | |||||
EV-to-FCF | -13.61 | |||||
| Price-to-Net-Current-Asset-Value | 3.67 | |||||
| Price-to-Net-Cash | 3.7 | |||||
Earnings Yield (Greenblatt) % | -9.24 | |||||
FCF Yield % | -5.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MLYS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mineralys Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.05 | ||
| Beta | 0.6992 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 1.38 | ||
| Volatility % | 150.91 | ||
| 14-Day RSI | 55.84 | ||
| 14-Day ATR ($) | 1.548675 | ||
| 20-Day SMA ($) | 26.53825 | ||
| 12-1 Month Momentum % | 62.3 | ||
| 52-Week Range ($) | 12.59 - 47.65 | ||
| Shares Outstanding (Mil) | 88.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mineralys Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mineralys Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 16:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 14:40 | 22.50 (-5.30%) | ||
| Guidance call for 2026 | 2026-06-03 07:35 | 28.85 (-6.03%) | ||
| General meeting for 2026 | 2026-05-21 13:30 | 28.43 (+7.28%) | ||
| Guidance call for 2026 | 2026-05-12 09:20 | 29.73 (+0.07%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 29.28 (-2.40%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 29.28 (-2.40%) |
Show
Entries
Mineralys Therapeutics Inc Frequently Asked Questions
What is Mineralys Therapeutics Inc(MLYS)'s stock price today?
The current price of MLYS is $28.38. The 52 week high of MLYS is $47.65 and 52 week low is $12.59.
When is next earnings date of Mineralys Therapeutics Inc(MLYS)?
The next earnings date of Mineralys Therapeutics Inc(MLYS) is 2026-08-12 Est..
Does Mineralys Therapeutics Inc(MLYS) pay dividends? If so, how much?
Mineralys Therapeutics Inc(MLYS) does not pay dividend.
Guru Commentaries on NAS:MLYS
No articles.
Press Release
Articles on Mineralys Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers